Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986416 (Bristol Myers Squibb)
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BMS-986416 is an investigational bispecific monoclonal antibody developed by Bristol Myers Squibb that simultaneously targets two inhibitory immune checkpoint receptors: T-cell immunoreceptor with Ig and ITIM domains (TIGIT) and Poliovirus receptor-related immunoglobulin domain-containing protein (PVRIG, also known as CD112R). Both TIGIT and PVRIG are expressed on T cells and natural killer (NK) cells and contribute to immune evasion by tumors. By blocking these pathways, BMS-986416 aims to restore and enhance anti-tumor immune responses. It is currently being evaluated in clinical trials for patients with advanced solid tumors, both as a monotherapy and in combination with other immunotherapies such as the PD-1 inhibitor nivolumab.
- Other names
- TIGIT x PVRIG bispecific antibody
02
Targets
TGFB1 (Transforming growth factor Beta-1 proprotein)TGFB3 (Transforming growth factor beta 3)PVRIG (Poliovirus receptor related immunoglobulin domain containing protein)TIGIT (T cell immunoreceptor with Ig and ITIM domains)
Beyond the preview
Go deeper on BMS-986416 (Bristol Myers Squibb).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-986416 (Bristol Myers Squibb).